Hospitals that give stem cell transplants or CAR T-cell therapy can be inspected against international standards. To pass, a programme must show an experienced team, a minimum number of new patients a year, medicines available at any hour, access to intensive care or emergency services, a quality plan, and that it reviews its results. The standards describe a minimum, not best practice.
The FACT-JACIE standards (haematopoietic cellular therapy, 9th edition version 9.1; immune effector cells, 3rd edition version 3.1; both effective 2 February 2026) are requirements for accreditation, not graded clinical recommendations. Each standard is a 'shall' (to be complied with at all times) or a 'should' (recommended, alternatives allowed, an explanation required for deviation). The notice in both documents states that they provide minimum guidelines and are not intended to establish best practices.
For a clinical programme the core requirements are: a designated team of a Clinical Program Director, a Quality Manager and at least one further attending physician, in place and treating for at least twelve months before first accreditation (B1.3); a director with at least two years as an attending physician managing transplant and cellular therapy patients (B3.1.1.1); a minimum number of new patients (Appendix I: at a single adult or paediatric site, 5 autologous recipients for an autologous-only programme, 10 allogeneic recipients for an allogeneic and autologous programme, and 3 immune effector cell recipients within a transplant programme, in the twelve months before accreditation and on average each year after; the immune effector cell standards, written for programmes that do not transplant, set 5 new patients at a single adult or paediatric site); access to intensive care or emergency services (B2.11); a pharmacy with 24-hour availability and prompt access to medicines for expected complications including cytokine release syndrome (B2.12); a written quality management plan (B4.2); complete data for the CIBMTR or EBMT registry forms (B9.2, a 'shall' in the transplant standards and a 'should' in the immune effector cell standards); and, for immune effector cells, regular assessment for cytokine release syndrome and neurological complications with a written escalation plan (B7.8).
On outcomes the transplant standards say 'should': one-year survival within or above the expected range against national or international data, with a corrective action plan required ('shall') if it is not met (B4.7.5). The immune effector cell standards have no survival standard; they require review of outcomes against criteria the programme sets (B4.7).
The two bodies differ on the cycle: three years for FACT-accredited programmes and four years for JACIE-certified programmes. Whether accreditation is required for a centre to give a licensed CAR T-cell product, or to be paid for a transplant, is decided by regulators, manufacturers and payers in each country and is not in the standards.
Why: The standards ask for a team, not one expert, and for that team to have been giving cellular therapy for at least twelve months before it is first accredited.
“The Clinical Program shall have a designated cellular therapy team that includes a Clinical Program Director, a Quality Manager, and a minimum of one (1) additional transplant or cellular therapy attending physician, as applicable.”
Foundation for the Accreditation of Cellular Therapy (FACT) and the Joint Assurance Committee of ISCT and EBMT (JACIE) 2025 · shall (B1.3)
Why: The director oversees the medical care given by everyone in the programme, so the standards ask that they have managed these patients themselves through the whole course of care.
“The Clinical Program Director shall have a minimum of two (2) years of experience as an attending physician responsible for the direct clinical management of HPC transplant and cellular therapy patients throughout the continuum of care.”
Foundation for the Accreditation of Cellular Therapy (FACT) and the Joint Assurance Committee of ISCT and EBMT (JACIE) 2025 · shall (B3.1.1.1)
Why: The standards set a floor on how many new patients a programme treats. They give no reason for the particular numbers.
“The Clinical Program shall comply with the minimum number of new patients for accreditation as defined in Appendix I.”
Foundation for the Accreditation of Cellular Therapy (FACT) and the Joint Assurance Committee of ISCT and EBMT (JACIE) 2025 · shall (B1.7)
Why: The standards ask for written guidelines on communication, monitoring and prompt triage or transfer, so the route to intensive care is settled before it is needed.
“There shall be access to an intensive care unit or emergency services.”
Foundation for the Accreditation of Cellular Therapy (FACT) and the Joint Assurance Committee of ISCT and EBMT (JACIE) 2025 · shall (B2.11)
Why: The standards ask that the pharmacy can get the medicines for expected complications promptly for each patient who receives a cell product.
“The pharmacy shall have prompt access to medications adequate to treat expected complications of cellular therapy, including cytokine release syndrome (CRS), for each recipient of a cellular therapy product.”
Foundation for the Accreditation of Cellular Therapy (FACT) and the Joint Assurance Committee of ISCT and EBMT (JACIE) 2025 · shall (B2.12.1)
Why: The plan has to cover, among other things, how errors, accidents, adverse events and complaints are detected, investigated and recorded.
“The Clinical Program shall establish and maintain a written Quality Management Plan (QM Plan).”
Foundation for the Accreditation of Cellular Therapy (FACT) and the Joint Assurance Committee of ISCT and EBMT (JACIE) 2025 · shall (B4.2)
Why: This is a recommendation in the transplant standards, not a requirement; what is required is a corrective action plan when the expected survival is not met.
“The Clinical Program should achieve one-year survival outcome within or above the expected range when compared to national or international outcome data.”
Foundation for the Accreditation of Cellular Therapy (FACT) and the Joint Assurance Committee of ISCT and EBMT (JACIE) 2025 · should (B4.7.5)
Why: Transplant programmes must also submit these data to a national or international database. In the immune effector cell standards, for programmes that do not transplant, collecting them is recommended, not required.
“The Clinical Program shall collect and maintain complete and accurate data necessary to complete the Transplant Essential Data Forms of the CIBMTR or the Data Collection Forms of the EBMT.”
Foundation for the Accreditation of Cellular Therapy (FACT) and the Joint Assurance Committee of ISCT and EBMT (JACIE) 2025 · shall (B9.2)
Why: The standards name these two complications as the ones regular assessment must be able to detect.
“There shall be regular assessment of the recipient to detect complications, including CRS and neurologic dysfunction.”
Foundation for the Accreditation of Cellular Therapy (FACT) and the Joint Assurance Committee of ISCT and EBMT (JACIE) 2025 · shall (B7.8.2)
Why: A plan written in advance means staff do not have to work out whom to call and what to do at the time. The standards also ask that the ward, intensive care, the emergency department and pharmacy are told in a timely way.
“There shall be a written plan for rapid escalation of care, increased intensity of monitoring, and relevant workup to address complications.”
Foundation for the Accreditation of Cellular Therapy (FACT) and the Joint Assurance Committee of ISCT and EBMT (JACIE) 2025 · shall (B7.8.3)
Why: After discharge the patient, their carers and other doctors may be the ones looking after them, so the standards ask that each is given instructions specific to the cell therapy.
“There shall be a process to provide cellular therapy-specific instructions for post-discharge care to the recipient, caregivers, and other health care providers who may provide care.”
Foundation for the Accreditation of Cellular Therapy (FACT) and the Joint Assurance Committee of ISCT and EBMT (JACIE) 2025 · shall (B7.9.1.1)
Why: A centre can tell you whether it is accredited, and for which treatments, and what that covers.
Common practice: The standards are written for programmes and say nothing to patients. FACT and JACIE each publish which programmes they have accredited; those lists were not read for this page.
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
The joint international standards are the FACT-JACIE International Standards, 9th edition version 9.1 for haematopoietic cellular therapy and 3rd edition version 3.1 for immune effector cells, both effective 2 February 2026 and both listed as current by FACT and by EBMT on 17 November 2026. FACT says the immune effector cell standards are for programmes that do not transplant, and that programmes doing both should use the haematopoietic standards. FACT alone also publishes a first edition of standards for immune effector cells in community clinics, which was not read. No competing standard from another body was found; the two bodies have reviewed and developed the standards jointly since the second edition in 2002. They are requirements for accreditation, not graded evidence, and they state their own limit: they are minimum guidelines and are not intended to establish best practices. The two bodies apply them on different cycles, three years for FACT and four years for JACIE. The firmest requirements are worded 'shall': the team and its experience, the minimum patient numbers, intensive care and pharmacy cover, the quality plan, registry data (in the transplant standards; 'should' in the immune effector cell standards), and monitoring for cytokine release syndrome and neurological complications. Meeting an expected one-year survival is worded 'should' in the transplant standards, with a corrective action plan required when it is not met.
Foundation for the Accreditation of Cellular Therapy (FACT) and the Joint Assurance Committee of ISCT and EBMT (JACIE) 2025 · Foundation for the Accreditation of Cellular Therapy (FACT) and the Joint Assurance Committee of ISCT and EBMT (JACIE) 2025 · Foundation for the Accreditation of Cellular Therapy (FACT) 2026
Where it differs: FACT began its inspection and accreditation programme in North America in 1997; JACIE was established in 1999 by EBMT and ISCT. The standards are shared; the length of the cycle is not: "At publication of these Standards, this period is three (3) years for FACT-accredited programs and four (4) years for JACIE-certified programs."
Evidence: A definition in the standards themselves. No comparison of outcomes under the two cycles is given.
Where it differs: A 'shall' has to be met at all times. A 'should' is recommended and a programme may do something else: "When an applicant deviates from a “should” standard, an explanation, but no change in practice, is required." Survival against expected results, and setting a benchmark for deaths not due to relapse at 100 days, are 'should' standards.
Evidence: The standards' own definitions (introduction and A1.1). The corrective action plan after a missed survival expectation is a 'shall'.
Where it differs: Appendix I sets different floors. At a single site treating adults or children: 5 autologous recipients for an autologous-only programme, 10 allogeneic recipients for a programme doing both, and 3 immune effector cell recipients within a transplant programme, in the twelve months before first accreditation and as a yearly average within the cycle. Programmes on several sites, or treating both adults and children, have their own rows, which are not reproduced here. The immune effector cell standards have their own Appendix I for a clinical service that gives immune effector cell therapy and does not transplant: 5 new patients at a single site treating adults or children, on the same two time frames. That appendix also describes an optional provisional accreditation, for which no patient number is required.
Evidence: The haematopoietic appendix introduces the table with: "Clinical Programs shall transplant at least the following number of new patients". A new patient is one who received a first transplant, or a first immune effector cell product, of that type in the period. The standards give no evidence for the particular numbers.
Foundation for the Accreditation of Cellular Therapy (FACT) and the Joint Assurance Committee of ISCT and EBMT (JACIE) 2025 · Foundation for the Accreditation of Cellular Therapy (FACT) and the Joint Assurance Committee of ISCT and EBMT (JACIE) 2025
| Recommendation | Grade, as printed | Source |
|---|---|---|
| What 'shall' and 'should' mean in the standards “For purposes of these Standards, the term “shall” means that the Standard is to be complied with at all times.” | definition (A1.1) | Foundation for the Accreditation of Cellular Therapy (FACT) and the Joint Assurance Committee of ISCT and EBMT (JACIE) 2025 |
| The standards are a minimum and not best practice “These Standards are designed to provide minimum guidelines for programs, facilities, and individuals performing cellular therapy or providing support services for such procedures.” | notice (both documents) | Foundation for the Accreditation of Cellular Therapy (FACT) and the Joint Assurance Committee of ISCT and EBMT (JACIE) 2025 |
| The same notice opens the immune effector cell standards “These Standards are not intended to establish best practices or include all procedures and practices that a program, facility, or individual should implement if the standard of practice in the community or applicable governmental laws establish additional requirements.” | notice | Foundation for the Accreditation of Cellular Therapy (FACT) and the Joint Assurance Committee of ISCT and EBMT (JACIE) 2025 |
| The team must have been in place and treating for at least twelve months before first accreditation “The designated team shall have been in place and performing cellular therapy for at least twelve (12) months preceding initial accreditation.” | shall (B1.3) | Foundation for the Accreditation of Cellular Therapy (FACT) and the Joint Assurance Committee of ISCT and EBMT (JACIE) 2025 |
| Written guidance for triage or transfer to intensive care “There shall be written guidelines for communication, patient monitoring, and prompt triage or transfer of patients to an intensive care unit, emergency department, or equivalent when appropriate.” | shall (B2.11.1) | Foundation for the Accreditation of Cellular Therapy (FACT) and the Joint Assurance Committee of ISCT and EBMT (JACIE) 2025 |
| A pharmacy with 24-hour availability “There shall be a pharmacy providing 24-hour availability of medications needed for the care of cellular therapy patients.” | shall (B2.12) | Foundation for the Accreditation of Cellular Therapy (FACT) and the Joint Assurance Committee of ISCT and EBMT (JACIE) 2025 |
| A corrective action plan when expected one-year survival is not met “If expected one-year survival outcome is not met, the Clinical Program shall implement a Corrective Action Plan that meets FACT or JACIE requirements.” | shall (B4.7.5.1) | Foundation for the Accreditation of Cellular Therapy (FACT) and the Joint Assurance Committee of ISCT and EBMT (JACIE) 2025 |
| Benchmarks for non-relapse mortality at 100 days “The Clinical Program should set benchmarks for non-relapse mortality at one hundred (100) days after cellular therapy product administration and describe the rationale and process for review in the QM Plan.” | should (B4.7.6) | Foundation for the Accreditation of Cellular Therapy (FACT) and the Joint Assurance Committee of ISCT and EBMT (JACIE) 2025 |
| The immune effector cell standards carry the same pharmacy requirement for cytokine release syndrome medicines “The pharmacy shall have prompt access to medications adequate to treat expected complications of cellular therapy, including cytokine release syndrome (CRS), for each recipient of a cellular therapy product.” | shall (B2.12.1) | Foundation for the Accreditation of Cellular Therapy (FACT) and the Joint Assurance Committee of ISCT and EBMT (JACIE) 2025 |
| Minimum new patient numbers apply to immune effector cell programmes as well “The Clinical Program shall comply with the minimum number of new patients for accreditation as defined in Appendix I.” | shall (B1.7) | Foundation for the Accreditation of Cellular Therapy (FACT) and the Joint Assurance Committee of ISCT and EBMT (JACIE) 2025 |
| Registry data collection is recommended, not required, in the immune effector cell standards “The Clinical Program should collect and maintain complete and accurate data necessary to complete the Cellular Therapy Essential Data forms of the CIBMTR or the Data Collection Forms of the EBMT.” | should (B9.2) | Foundation for the Accreditation of Cellular Therapy (FACT) and the Joint Assurance Committee of ISCT and EBMT (JACIE) 2025 |
| Transplant programmes submit their data to a national or international database “Clinical Programs shall submit the data specified in B9.2 for allogeneic and autologous transplants to a national or international database.” | shall (B9.2.1) | Foundation for the Accreditation of Cellular Therapy (FACT) and the Joint Assurance Committee of ISCT and EBMT (JACIE) 2025 |
Shares Leukapheresis to collect T cells for CAR T-cell manufacture, Referral and eligibility assessment for CAR T-cell therapy, ICANS after CAR T-cell therapy: ICE score, ASTCT grading, steroids and seizure management, Cytokine release syndrome after CAR T-cell therapy: ASTCT grading, tocilizumab and steroids.
Shares Leukapheresis to collect T cells for CAR T-cell manufacture, Referral and eligibility assessment for CAR T-cell therapy, ICANS after CAR T-cell therapy: ICE score, ASTCT grading, steroids and seizure management, Cytokine release syndrome after CAR T-cell therapy: ASTCT grading, tocilizumab and steroids.
Shares Apheresis (leukapheresis), Leukapheresis to collect T cells for CAR T-cell manufacture, Autologous stem cell transplant (high-dose therapy), Allogeneic stem cell transplantation.
Shares Who is supposed to be watching: EBMT, CIBMTR, FACT-JACIE, and what a survivor is actually offered, Autologous stem cell transplant (high-dose therapy), Allogeneic stem cell transplantation.
Shares Leukapheresis to collect T cells for CAR T-cell manufacture, Referral and eligibility assessment for CAR T-cell therapy, ICANS after CAR T-cell therapy: ICE score, ASTCT grading, steroids and seizure management, Cytokine release syndrome after CAR T-cell therapy: ASTCT grading, tocilizumab and steroids.
Shares Apheresis (leukapheresis), Leukapheresis to collect T cells for CAR T-cell manufacture, Autologous stem cell transplant (high-dose therapy).
Shares Leukapheresis to collect T cells for CAR T-cell manufacture, Referral and eligibility assessment for CAR T-cell therapy, ICANS after CAR T-cell therapy: ICE score, ASTCT grading, steroids and seizure management, Cytokine release syndrome after CAR T-cell therapy: ASTCT grading, tocilizumab and steroids.
Shares GVHD prophylaxis after allogeneic stem cell transplant: choosing the regimen, Autologous stem cell transplant (high-dose therapy), Allogeneic stem cell transplantation.